RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AssigneeSirna Therapeutics, Inc.
InventorsJames McSwiggen, Leonid Beigelman
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorsJames McSwiggen, Leonid Beigelman
Estimating the term…
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
A chemically modified double-stranded short interfering nucleic acid molecule that mediates RNA interference (RNAi) and comprising a sense strand and an antisense strand that are not connected via a linker molecule, wherein:
Dependencies are inferred from the claim text.